Telmitan Max 5 mg+80 mg (Tablet)
Unit Price: ৳ 20.00 (1 x 14: ৳ 280.00)
Strip Price: ৳ 280.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate telmisartan |
| Company | Opsonin pharma ltd |
| Also available as |
Indications
- Treatment of hypertension
- Combination therapy for blood pressure control
Pharmacology
- Combination of Telmisartan and Amiodipine
- Non-peptide angiotensin receptor blocker (ARB)
- Dihydropyridine calcium-channel blocker (CCB)
- Inhibition of angiotensin II
- Vasodilation and reduction in blood pressure
Dosage & Administration
- Initial therapy starting dose: 40/5 mg once daily
- Add-on therapy for inadequate blood pressure control
- Replacement therapy for simplification of drug regimen
- Maximum recommended dose: 80/10 mg once daily
Interaction
- No clinically significant interaction with acetaminophen, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen
- Possible inhibition of CYP2C19 metabolism
- Safe co-administration with thiazide diuretics, beta-blockers, ACE inhibitors, nitrates, digoxin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs
Contraindications
- Hypersensitivity to the product or its components
- Pregnancy & lactation
- Biliary obstructive disorders, severe hepatic impairment, hypotension, cardiogenic shock
Side Effects
- Dizziness
- Peripheral edema
- Migraine
- Bradycardia
- Hypotension
- Cough
- Abdominal pain
- Diarrhea
- Nausea
- Pruritus
- Myalgia
- Erectile dysfunction
- Chest pain
- Fatigue
Pregnancy & Lactation
- Pregnancy Categories C (first trimester) and D (second and third trimesters)
- Potential excretion in human milk
- Discontinue nursing if adverse effects on the infant are suspected
Precautions & Warnings
- Avoid fetal or neonatal exposure
- Correct volume or salt depletion before initiating therapy
- Monitor for worsening heart failure
- Avoid concomitant use of ACE inhibitor and angiotensin receptor blocker
- Titrate slowly in patients with hepatic or severe renal impairment
- Risk of myocardial infarction in patients with severe obstructive coronary artery disease
Use in Special Populations
- Pediatric use not established
- Initial therapy not recommended for patients ≥75 years old or with hepatic impairment
Overdose Effects
- Telmisartan overdose manifestations: hypotension, dizziness, tachycardia
- Amiodipine overdose manifestations: excessive vasodilation, marked hypotension, reflex tachycardia
- Supportive treatment for symptomatic hypotension
Therapeutic Class
Combined antihypertensive preparations
Storage Conditions
Store below 30°C, protect from light and high humidity, keep out of reach of children